Investor reaction to the deal was muted, with BMO Capital Markets analysts saying they "continue to look for more" from ...
Stocktwits on MSN
Bristol Myers Squibb To Acquire Orbital Therapeutics In $1.5B Deal
Bristol Myers Squibb (BMY) on Friday announced a definitive agreement to acquire privately held RNA-focused biotech firm ...
Bristol Myers Squibb (BMS) has agreed to acquire Orbital Therapeutics in a deal valued at $1.5bn. Robert Plenge, executive VP ...
Bristol Myers Squibb (BMS) has announced the acquisition of Orbital Therapeutics, a privately held biotech specializing in ...
GlobalData on MSN
BMS expands CAR-T portfolio with $1.5bn Orbital buyout
BMS, which already has two FDA-approved CAR T-cell therapies, is eyeing entry into the growing in vivo market.
Bristol Myers Squibb (BMS) announced a definitive agreement in which BMS will acquire Orbital Therapeutics along with its investigational next-generation CAR T-cell therapy OTX-201. The acquisition is ...
Bristol Myers Squibb Strengthens and Diversifies Cell Therapy Portfolio with Acquisition of Orbital Therapeutics ...
The drugmaker has launched an international Phase I trial, dubbed Breakfree-2, in seven countries to test the autologous therapy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback